{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T12:18:30Z","timestamp":1795004310007,"version":"4.9.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T00:00:00Z","timestamp":1687305600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T00:00:00Z","timestamp":1687305600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R24GM137782"],"award-info":[{"award-number":["R24GM137782"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R24GM137782"],"award-info":[{"award-number":["R24GM137782"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R24GM137782"],"award-info":[{"award-number":["R24GM137782"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R24GM137782"],"award-info":[{"award-number":["R24GM137782"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R24GM137782"],"award-info":[{"award-number":["R24GM137782"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["DMR-1933525"],"award-info":[{"award-number":["DMR-1933525"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["DMR-1933525"],"award-info":[{"award-number":["DMR-1933525"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["DMR-1933525"],"award-info":[{"award-number":["DMR-1933525"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["DMR-1933525"],"award-info":[{"award-number":["DMR-1933525"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["DMR-1933525"],"award-info":[{"award-number":["DMR-1933525"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000015","name":"U.S. Department of Energy","doi-asserted-by":"publisher","award":["DE-SC0015662"],"award-info":[{"award-number":["DE-SC0015662"]}],"id":[{"id":"10.13039\/100000015","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The glycosylation on the spike (S) protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, modulates the viral infection by altering conformational dynamics, receptor interaction and host immune responses. Several variants of concern (VOCs) of SARS-CoV-2 have evolved during the pandemic, and crucial mutations on the S protein of the virus have led to increased transmissibility and immune escape. In this study, we compare the site-specific glycosylation and overall glycomic profiles of the wild type Wuhan-Hu-1 strain (WT) S protein and five VOCs of SARS-CoV-2: Alpha, Beta, Gamma, Delta and Omicron. Interestingly, both N- and O-glycosylation sites on the S protein are highly conserved among the spike mutant variants, particularly at the sites on the receptor-binding domain (RBD). The conservation of glycosylation sites is noteworthy, as over 2 million SARS-CoV-2 S protein sequences have been reported with various amino acid mutations. Our detailed profiling of the glycosylation at each of the individual sites of the S protein across the variants revealed intriguing possible association of glycosylation pattern on the variants and their previously reported infectivity. While the sites are conserved, we observed changes in the N- and O-glycosylation profile across the variants. The newly emerged variants, which showed higher resistance to neutralizing antibodies and vaccines, displayed a decrease in the overall abundance of complex-type glycans with both fucosylation and sialylation and an increase in the oligomannose-type glycans across the sites. Among the variants, the glycosylation sites with significant changes in glycan profile were observed at both the\n                    <jats:italic>N<\/jats:italic>\n                    -terminal domain and RBD of S protein, with Omicron showing the highest deviation. The increase in oligomannose-type happens sequentially from Alpha through Delta. Interestingly, Omicron does not contain more oligomannose-type glycans compared to Delta but does contain more compared to the WT and other VOCs. O-glycosylation at the RBD showed lower occupancy in the VOCs in comparison to the WT. Our study on the sites and pattern of glycosylation on the SARS-CoV-2 S proteins across the VOCs may help to understand how the virus evolved to trick the host immune system. Our study also highlights how the SARS-CoV-2 virus has conserved both\n                    <jats:italic>N<\/jats:italic>\n                    - and\n                    <jats:italic>O<\/jats:italic>\n                    - glycosylation sites on the S protein of the most successful variants even after undergoing extensive mutations, suggesting a correlation between infectivity\/ transmissibility and glycosylation.\n                  <\/jats:p>","DOI":"10.1038\/s41598-023-33088-0","type":"journal-article","created":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T06:01:54Z","timestamp":1687327314000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":70,"title":["Site specific N- and O-glycosylation mapping of the spike proteins of SARS-CoV-2 variants of concern"],"prefix":"10.1038","volume":"13","author":[{"given":"Asif","family":"Shajahan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren E.","family":"Pepi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhoj","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan B.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parastoo","family":"Azadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,21]]},"reference":[{"key":"33088_CR1","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1021\/acs.analchem.0c03173","volume":"93","author":"M Sanda","year":"2021","unstructured":"Sanda, M., Morrison, L. & Goldman, R. N- and O-glycosylation of the SARS-CoV-2 spike protein. Anal. Chem. 93, 2003\u20132009. https:\/\/doi.org\/10.1021\/acs.analchem.0c03173 (2021).","journal-title":"Anal. Chem."},{"key":"33088_CR2","first-page":"14","volume":"24","author":"AS Gleinich","year":"2021","unstructured":"Gleinich, A. S., Pepi, L. E., Shajahan, A., Heiss, C. & Azadi, P. Vaccines and therapeutics for COVID-19 - How can understanding SARS-CoV-2 glycosylation lead to pharmaceutical advances?. Am. Pharm. Rev. 24, 14\u201321 (2021).","journal-title":"Am. Pharm. Rev."},{"key":"33088_CR3","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1093\/glycob\/cwaa101","volume":"31","author":"A Shajahan","year":"2021","unstructured":"Shajahan, A. et al. Comprehensive characterization of N-and O-glycosylation of SARS-CoV-2 human receptor angiotensin converting enzyme 2. Glycobiology 31, 410\u2013424 (2021).","journal-title":"Glycobiology"},{"key":"33088_CR4","doi-asserted-by":"publisher","DOI":"10.1007\/s00216-021-03499-x","author":"A Shajahan","year":"2021","unstructured":"Shajahan, A., Pepi, L. E., Rouhani, D. S., Heiss, C. & Azadi, P. Glycosylation of SARS-CoV-2: Structural and functional insights. Anal. Bioanal. Chem. https:\/\/doi.org\/10.1007\/s00216-021-03499-x (2021).","journal-title":"Anal. Bioanal. Chem."},{"key":"33088_CR5","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1093\/glycob\/cwaa042%JGlycobiology","volume":"30","author":"A Shajahan","year":"2020","unstructured":"Shajahan, A., Supekar, N. T., Gleinich, A. S. & Azadi, P. Deducing the N- and O-glycosylation profile of the spike protein of novel coronavirus SARS-CoV-2. Glycobiology 30, 981\u2013988. https:\/\/doi.org\/10.1093\/glycob\/cwaa042%JGlycobiology (2020).","journal-title":"Glycobiology"},{"key":"33088_CR6","doi-asserted-by":"publisher","DOI":"10.1093\/glycob\/cwab044","author":"NT Supekar","year":"2021","unstructured":"Supekar, N. T. et al. Variable posttranslational modifications of severe acute respiratory syndrome coronavirus 2 nucleocapsid protein. Glycobiology https:\/\/doi.org\/10.1093\/glycob\/cwab044 (2021).","journal-title":"Glycobiology"},{"key":"33088_CR7","unstructured":"University, C. F. S. S. A. E. C. A. J. H. COVID-19 Data Repository by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University, https:\/\/github.com\/CSSEGISandData\/COVID-19 (2021)."},{"key":"33088_CR8","unstructured":"Organization, W. H. WHO Coronavirus (COVID-19) Dashboard, https:\/\/covid19.who.int\/ (2021)."},{"key":"33088_CR9","unstructured":"Administration, U. S. F. a. D. FDA Approves First COVID-19 Vaccine, https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-covid-19-vaccine (2021)."},{"key":"33088_CR10","unstructured":"Administration, U. S. F. A. D. Emergency Use Authorization, https:\/\/www.fda.gov\/emergency-preparedness-and-response\/mcm-legal-regulatory-and-policy-framework\/emergency-use-authorization (2021)."},{"key":"33088_CR11","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1056\/NEJMc2100362","volume":"384","author":"SS Abdool Karim","year":"2021","unstructured":"Abdool Karim, S. S. & de Oliveira, T. New SARS-CoV-2 variants\u2014clinical, public health, and vaccine implications. N. Engl. J. Med. 384, 1866\u20131868 (2021).","journal-title":"N. Engl. J. Med."},{"key":"33088_CR12","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1126\/science.abi9745","volume":"373","author":"Y Cai","year":"2021","unstructured":"Cai, Y. et al. Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants. Science 373, 642\u2013648. https:\/\/doi.org\/10.1126\/science.abi9745 (2021).","journal-title":"Science"},{"key":"33088_CR13","doi-asserted-by":"publisher","first-page":"2939","DOI":"10.1016\/j.cell.2021.03.055","volume":"184","author":"W Dejnirattisai","year":"2021","unstructured":"Dejnirattisai, W. et al. Antibody evasion by the P1 strain of SARS-CoV-2. Cell 184, 2939\u20132954. https:\/\/doi.org\/10.1016\/j.cell.2021.03.055 (2021).","journal-title":"Cell"},{"key":"33088_CR14","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1056\/NEJMoa2108891","volume":"385","author":"J Lopez Bernal","year":"2021","unstructured":"Lopez Bernal, J. et al. Effectiveness of Covid-19 vaccines against the B. 1.617.2 delta variant. N. Engl. J. Med. 385, 585\u2013594 (2021).","journal-title":"N. Engl. J. Med."},{"key":"33088_CR15","doi-asserted-by":"crossref","unstructured":"Mohammadi, M., Shayestehpour, M. & Mirzaei, H. The impact of spike mutated variants of SARS-CoV2 [Alpha, Beta, Gamma, Delta, and Lambda] on the efficacy of subunit recombinant vaccines. Braz. J. Infect. Dis. 25 (2021).","DOI":"10.1016\/j.bjid.2021.101606"},{"key":"33088_CR16","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s41586-021-03324-6","volume":"592","author":"Z Wang","year":"2021","unstructured":"Wang, Z. et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature 592, 616\u2013622. https:\/\/doi.org\/10.1038\/s41586-021-03324-6 (2021).","journal-title":"Nature"},{"key":"33088_CR17","unstructured":"Organization, W. H. Tracking SARS-CoV-2 Variants, https:\/\/www.who.int\/en\/activities\/tracking-SARS-CoV-2-variants\/ (2021)."},{"issue":"24","key":"33088_CR18","doi-asserted-by":"publisher","first-page":"e85","DOI":"10.1056\/NEJMoa2114228","volume":"385","author":"Y Goldberg","year":"2021","unstructured":"Goldberg, Y. et al. Waning immunity after the BNT162b2 vaccine in Israel. N. Engl. J. Med. 385(24), e85 (2021).","journal-title":"N. Engl. J. Med."},{"key":"33088_CR19","doi-asserted-by":"publisher","first-page":"2100557","DOI":"10.2807\/1560-7917.ES.2021.26.26.2100557","volume":"26","author":"Y Lustig","year":"2021","unstructured":"Lustig, Y. et al. Neutralising capacity against Delta (B. 1.617. 2) and other variants of concern following Comirnaty (BNT162b2, BioNTech\/Pfizer) vaccination in health care workers, Israel. Eurosurveillance 26, 2100557 (2021).","journal-title":"Eurosurveillance"},{"key":"33088_CR20","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/d41586-021-03552-w","volume":"600","author":"E Callaway","year":"2021","unstructured":"Callaway, E. Heavily mutated Omicron variant puts scientists on alert. Nature 600, 21. https:\/\/doi.org\/10.1038\/d41586-021-03552-w (2021).","journal-title":"Nature"},{"key":"33088_CR21","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41423-021-00836-z","volume":"19","author":"J Hu","year":"2022","unstructured":"Hu, J. et al. Increased immune escape of the new SARS-CoV-2 variant of concern Omicron. Cell. Mol. Immunol. 19, 293\u2013295 (2022).","journal-title":"Cell. Mol. Immunol."},{"key":"33088_CR22","doi-asserted-by":"publisher","first-page":"e02077","DOI":"10.1128\/jvi.02077-21","volume":"96","author":"C Jung","year":"2022","unstructured":"Jung, C. et al. Omicron: What makes the latest SARS-CoV-2 variant of concern so concerning?. J. Virol. 96, e02077-e12021 (2022).","journal-title":"J. Virol."},{"key":"33088_CR23","doi-asserted-by":"publisher","first-page":"102779","DOI":"10.1016\/j.jaut.2021.102779","volume":"126","author":"SR Kannan","year":"2022","unstructured":"Kannan, S. R. et al. Omicron SARS-CoV-2 variant: Unique features and their impact on pre-existing antibodies. J. Autoimmun. 126, 102779 (2022).","journal-title":"J. Autoimmun."},{"key":"33088_CR24","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1016\/j.cell.2021.03.052","volume":"184","author":"NL Washington","year":"2021","unstructured":"Washington, N. L. et al. Emergence and rapid transmission of SARS-CoV-2 B.1.1.7 in the United States. Cell 184, 2587\u20132594. https:\/\/doi.org\/10.1016\/j.cell.2021.03.052 (2021).","journal-title":"Cell"},{"key":"33088_CR25","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1126\/science.abb9983","volume":"369","author":"Y Watanabe","year":"2020","unstructured":"Watanabe, Y., Allen, J. D., Wrapp, D., McLellan, J. S. & Crispin, M. Site-specific glycan analysis of the SARS-CoV-2 spike. Science 369, 330\u2013333. https:\/\/doi.org\/10.1126\/science.abb9983 (2020).","journal-title":"Science"},{"key":"33088_CR26","doi-asserted-by":"publisher","first-page":"166762","DOI":"10.1016\/j.jmb.2020.166762","volume":"433","author":"JD Allen","year":"2021","unstructured":"Allen, J. D., Watanabe, Y., Chawla, H., Newby, M. L. & Crispin, M. Subtle influence of ACE2 glycan processing on SARS-CoV-2 recognition. J Mol Biol 433, 166762 (2021).","journal-title":"J Mol Biol"},{"key":"33088_CR27","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1126\/science.abc0870","volume":"369","author":"KK Chan","year":"2020","unstructured":"Chan, K. K. et al. Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2. Science 369, 1261\u20131265 (2020).","journal-title":"Science"},{"key":"33088_CR28","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.cell.2020.09.033","volume":"183","author":"TM Clausen","year":"2020","unstructured":"Clausen, T. M. et al. SARS-CoV-2 infection depends on cellular heparan sulfate and ACE2. Cell 183, 1043-1057.e1015. https:\/\/doi.org\/10.1016\/j.cell.2020.09.033 (2020).","journal-title":"Cell"},{"key":"33088_CR29","doi-asserted-by":"publisher","first-page":"608765","DOI":"10.3389\/fpubh.2020.608765","volume":"8","author":"CA Devaux","year":"2020","unstructured":"Devaux, C. A., Pinault, L., Osman, I. O. & Raoult, D. Can ACE2 receptor polymorphism predict species susceptibility to SARS-CoV-2?. Public Health Front. 8, 608765 (2020).","journal-title":"Public Health Front."},{"key":"33088_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s42003-021-02030-3","volume":"4","author":"K Suryamohan","year":"2021","unstructured":"Suryamohan, K. et al. Human ACE2 receptor polymorphisms and altered susceptibility to SARS-CoV-2. Commun. Biol. 4, 1\u201311 (2021).","journal-title":"Commun. Biol."},{"key":"33088_CR31","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1021\/acscentsci.1c00058","volume":"7","author":"J Brun","year":"2021","unstructured":"Brun, J. et al. Assessing antigen structural integrity through glycosylation analysis of the SARS-CoV-2 viral spike. ACS Cent. Sci. 7, 586\u2013593. https:\/\/doi.org\/10.1021\/acscentsci.1c00058 (2021).","journal-title":"ACS Cent. Sci."},{"key":"33088_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-021-00545-2","author":"W Tian","year":"2021","unstructured":"Tian, W. et al. O-glycosylation pattern of the SARS-CoV-2 spike protein reveals an \u201cO-Follow-N\u201d rule. Cell Res. https:\/\/doi.org\/10.1038\/s41422-021-00545-2 (2021).","journal-title":"Cell Res."},{"key":"33088_CR33","doi-asserted-by":"publisher","first-page":"167332","DOI":"10.1016\/j.jmb.2021.167332","volume":"434","author":"H Chawla","year":"2022","unstructured":"Chawla, H. et al. Glycosylation and serological reactivity of an expression-enhanced SARS-CoV-2 viral spike mimetic. J. Mol. Biol. 434, 167332. https:\/\/doi.org\/10.1016\/j.jmb.2021.167332 (2022).","journal-title":"J. Mol. Biol."},{"key":"33088_CR34","doi-asserted-by":"publisher","first-page":"167928","DOI":"10.1016\/j.jmb.2022.167928","volume":"435","author":"ML Newby","year":"2023","unstructured":"Newby, M. L. et al. Variations within the glycan shield of SARS-CoV-2 Impact viral spike dynamics. J. Mol. Biol. 435, 167928. https:\/\/doi.org\/10.1016\/j.jmb.2022.167928 (2023).","journal-title":"J. Mol. Biol."},{"key":"33088_CR35","doi-asserted-by":"publisher","first-page":"4483","DOI":"10.1007\/s00216-017-0406-7","volume":"409","author":"A Shajahan","year":"2017","unstructured":"Shajahan, A., Heiss, C., Ishihara, M. & Azadi, P. Glycomic and glycoproteomic analysis of glycoproteins\u2014a tutorial. Anal. Bioanal. Chem. 409, 4483\u20134505 (2017).","journal-title":"Anal. Bioanal. Chem."},{"key":"33088_CR36","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1021\/acs.analchem.8b05146","volume":"91","author":"A Shajahan","year":"2018","unstructured":"Shajahan, A., Supekar, N., Heiss, C. & Azadi, P. High-throughput automated micro-permethylation for glycan structure analysis. Anal. Chem. 91, 1237\u20131240 (2018).","journal-title":"Anal. Chem."},{"key":"33088_CR37","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/0003-2697(92)90048-C","volume":"203","author":"KR Anumula","year":"1992","unstructured":"Anumula, K. R. & Taylor, P. B. A comprehensive procedure for preparation of partially methylated alditol acetates from glycoprotein carbohydrates. Anal. BioChem. 203, 101\u2013108 (1992).","journal-title":"Anal. BioChem."},{"key":"33088_CR38","doi-asserted-by":"publisher","first-page":"10734","DOI":"10.1021\/acs.analchem.7b01730","volume":"89","author":"A Shajahan","year":"2017","unstructured":"Shajahan, A., Supekar, N. T., Heiss, C., Ishihara, M. & Azadi, P. Tool for rapid analysis of glycopeptide by permethylation via one-pot site mapping and glycan analysis. Anal. Chem. 89, 10734\u201310743 (2017).","journal-title":"Anal. Chem."},{"key":"33088_CR39","first-page":"14","volume":"35","author":"A Shajahan","year":"2017","unstructured":"Shajahan, A. & Azadi, P. Mass spectrometry techniques to unravel the heterogeneity of glycoproteins. LC-GC North Am. 35, 14\u201323 (2017).","journal-title":"LC-GC North Am."},{"key":"33088_CR40","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1126\/science.1154315","volume":"320","author":"RM Anthony","year":"2008","unstructured":"Anthony, R. M. et al. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 320, 373\u2013376 (2008).","journal-title":"Science"},{"key":"33088_CR41","doi-asserted-by":"publisher","first-page":"13.20.11","DOI":"10.1002\/0471250953.bi1320s40","volume":"40","author":"M Bern","year":"2012","unstructured":"Bern, M., Kil, Y. J. & Becker, C. Byonic: Advanced peptide and protein identification software. Curr. Protoc. Bioinform. 40, 13.20.11-13.20.14 (2012).","journal-title":"Curr. Protoc. Bioinform."},{"key":"33088_CR42","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1021\/pr7008252","volume":"7","author":"A Ceroni","year":"2008","unstructured":"Ceroni, A. et al. GlycoWorkbench: A tool for the computer-assisted annotation of mass spectra of glycans. J. Proteome Res. 7, 1650\u20131659 (2008).","journal-title":"J. Proteome Res."},{"key":"33088_CR43","unstructured":"Organization, W. H. Tracking SARS-CoV-2 Variants, https:\/\/www.who.int\/activities\/tracking-SARS-CoV-2-variants (2022)."},{"key":"33088_CR44","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ijbiomac.2022.03.058","volume":"208","author":"PFN Souza","year":"2022","unstructured":"Souza, P. F. N. et al. The spike glycoprotein of SARS-CoV-2: A review of how mutations of spike glycoproteins have driven the emergence of variants with high transmissibility and immune escape. Int. J. Biol. Macromol. 208, 105\u2013125. https:\/\/doi.org\/10.1016\/j.ijbiomac.2022.03.058 (2022).","journal-title":"Int. J. Biol. Macromol."},{"key":"33088_CR45","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1093\/glycob\/cwab102","volume":"32","author":"CW Kuo","year":"2022","unstructured":"Kuo, C. W. et al. Distinct shifts in site-specific glycosylation pattern of SARS-CoV-2 spike proteins associated with arising mutations in the D614G and Alpha variants. Glycobiology 32, 60\u201372. https:\/\/doi.org\/10.1093\/glycob\/cwab102 (2022).","journal-title":"Glycobiology"},{"key":"33088_CR46","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.crstbi.2022.01.002","volume":"4","author":"K Guruprasad","year":"2022","unstructured":"Guruprasad, K. Mutations in human SARS-CoV-2 spike proteins, potential drug binding and epitope sites for COVID-19 therapeutics development. Curr. Res. Struct. Biol. 4, 41\u201350. https:\/\/doi.org\/10.1016\/j.crstbi.2022.01.002 (2022).","journal-title":"Curr. Res. Struct. Biol."},{"key":"33088_CR47","doi-asserted-by":"publisher","first-page":"103712","DOI":"10.1016\/j.ebiom.2021.103712","volume":"74","author":"HC Huang","year":"2021","unstructured":"Huang, H. C. et al. Targeting conserved N-glycosylation blocks SARS-CoV-2 variant infection in vitro. EBioMedicine 74, 103712. https:\/\/doi.org\/10.1016\/j.ebiom.2021.103712 (2021).","journal-title":"EBioMedicine"},{"key":"33088_CR48","doi-asserted-by":"publisher","first-page":"77R","DOI":"10.1093\/glycob\/cwg075","volume":"13","author":"ES Trombetta","year":"2003","unstructured":"Trombetta, E. S. The contribution of N-glycans and their processing in the endoplasmic reticulum to glycoprotein biosynthesis. Glycobiology 13, 77R-91R. https:\/\/doi.org\/10.1093\/glycob\/cwg075 (2003).","journal-title":"Glycobiology"},{"key":"33088_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.medidd.2021.100114","author":"SS Goher","year":"2021","unstructured":"Goher, S. S., Ali, F. & Amin, M. The delta variant mutations in the receptor binding domain of SARS-CoV-2 show enhanced electrostatic interactions with the ACE2. Med. Drug Discov. https:\/\/doi.org\/10.1016\/j.medidd.2021.100114 (2021).","journal-title":"Med. Drug Discov."},{"key":"33088_CR50","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1038\/s41467-022-28324-6","volume":"13","author":"JW Saville","year":"2022","unstructured":"Saville, J. W. et al. Structural and biochemical rationale for enhanced spike protein fitness in delta and kappa SARS-CoV-2 variants. Nat. Commun. 13, 742. https:\/\/doi.org\/10.1038\/s41467-022-28324-6 (2022).","journal-title":"Nat. Commun."},{"key":"33088_CR51","doi-asserted-by":"publisher","first-page":"e1010260","DOI":"10.1371\/journal.ppat.1010260","volume":"18","author":"A Mittal","year":"2022","unstructured":"Mittal, A., Khattri, A. & Verma, V. Structural and antigenic variations in the spike protein of emerging SARS-CoV-2 variants. PLoS Pathog. 18, e1010260. https:\/\/doi.org\/10.1371\/journal.ppat.1010260 (2022).","journal-title":"PLoS Pathog."},{"key":"33088_CR52","doi-asserted-by":"publisher","first-page":"e2109905118","DOI":"10.1073\/pnas.2109905118","volume":"118","author":"L Zhang","year":"2021","unstructured":"Zhang, L. et al. Furin cleavage of the SARS-CoV-2 spike is modulated by O-glycosylation. Proc. Natl. Acad. Sci. 118, e2109905118 (2021).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"33088_CR53","doi-asserted-by":"publisher","first-page":"551","DOI":"10.3390\/v13040551","volume":"13","author":"I Bagdonaite","year":"2021","unstructured":"Bagdonaite, I. et al. Site-specific O-glycosylation analysis of SARS-CoV-2 spike protein produced in insect and human cells. Viruses 13, 551 (2021).","journal-title":"Viruses"},{"key":"33088_CR54","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1002\/jmv.27539","volume":"94","author":"MG Hossain","year":"2022","unstructured":"Hossain, M. G., Tang, Y. D., Akter, S. & Zheng, C. Roles of the polybasic furin cleavage site of spike protein in SARS-CoV-2 replication, pathogenesis, and host immune responses and vaccination. J. Med. Virol. 94, 1815\u20131820 (2022).","journal-title":"J. Med. Virol."},{"key":"33088_CR55","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1093\/glycob\/cwy021","volume":"28","author":"I Bagdonaite","year":"2018","unstructured":"Bagdonaite, I. & Wandall, H. H. Global aspects of viral glycosylation. Glycobiology 28, 443\u2013467. https:\/\/doi.org\/10.1093\/glycob\/cwy021 (2018).","journal-title":"Glycobiology"},{"key":"33088_CR56","doi-asserted-by":"publisher","first-page":"e1004784","DOI":"10.1371\/journal.ppat.1004784","volume":"11","author":"I Bagdonaite","year":"2015","unstructured":"Bagdonaite, I. et al. A strategy for O-glycoproteomics of enveloped viruses\u2014The O-glycoproteome of herpes simplex virus type 1. PLoS Pathog. 11, e1004784 (2015).","journal-title":"PLoS Pathog."},{"key":"33088_CR57","doi-asserted-by":"publisher","first-page":"10773","DOI":"10.1128\/JVI.01166-10","volume":"84","author":"J Arii","year":"2010","unstructured":"Arii, J. et al. A single-amino-acid substitution in herpes simplex virus 1 envelope glycoprotein B at a site required for binding to the paired immunoglobulin-like type 2 receptor \u03b1 (PILR\u03b1) abrogates PILR\u03b1-dependent viral entry and reduces pathogenesis. J. Virol. 84, 10773\u201310783 (2010).","journal-title":"J. Virol."},{"key":"33088_CR58","doi-asserted-by":"publisher","first-page":"8072","DOI":"10.1128\/JVI.00459-07","volume":"81","author":"E Falkowska","year":"2007","unstructured":"Falkowska, E., Kajumo, F., Garcia, E., Reinus, J. & Dragic, T. Hepatitis C virus envelope glycoprotein E2 glycans modulate entry, CD81 binding, and neutralization. J. Virol. 81, 8072\u20138079 (2007).","journal-title":"J. Virol."},{"key":"33088_CR59","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1089\/vim.2020.0174","volume":"34","author":"E Ramirez Hernandez","year":"2021","unstructured":"Ramirez Hernandez, E. et al. The role of the SARS-CoV-2 S-protein glycosylation in the interaction of SARS-CoV-2\/ACE2 and immunological responses. Viral. Immunol. 34, 165\u2013173 (2021).","journal-title":"Viral. Immunol."},{"key":"33088_CR60","doi-asserted-by":"publisher","DOI":"10.1093\/glycob\/cwad007","author":"Y Xie","year":"2023","unstructured":"Xie, Y. & Butler, M. Quantitative profiling of N-glycosylation of SARS-CoV-2 spike protein variants. Glycobiology https:\/\/doi.org\/10.1093\/glycob\/cwad007 (2023).","journal-title":"Glycobiology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-33088-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-33088-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-33088-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T06:03:22Z","timestamp":1687327402000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-33088-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,21]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["33088"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-33088-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2188138\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,21]]},"assertion":[{"value":"20 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10053"}}